PMID- 36952005
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20240416
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 10
DP  - 2023 Aug
TI  - Comparison of stereotactic body radiotherapy with and without lenvatinib for 
      advanced hepatocellular carcinoma: a propensity score analysis.
PG  - 7441-7452
LID - 10.1007/s00432-023-04652-y [doi]
AB  - PURPOSE: Lack of evidence on the benefit of stereotactic body radiotherapy (SBRT) 
      in combination with lenvatinib for advanced hepatocellular carcinoma (HCC). Our 
      research compared the efficacy and safety of SBRT plus lenvatinib versus SBRT 
      alone in clinical practice for the treatment of advanced HCC. METHODS: Propensity 
      score matching (PSM) analysis was used to reduce selection bias. Overall survival 
      (OS), progression-free survival (PFS), intrahepatic PFS (IHPFS), and objective 
      response rate (ORR) were compared between the two groups. Additionally, safety 
      profiles were also evaluated in the two groups. RESULTS: After PSM, 35 patients 
      from each group were selected and the date was compared. Compared with the SBRT 
      alone group, the median OS, PFS, and IHPFS were significantly prolonged in SBRT 
      plus lenvatinib group (median OS 16.8 vs. 11.0 months, pOS = 0.043; median PFS 
      9.1 vs. 3.7 months, pPFS < 0.001; median IHPFS 9.5 vs. 4.2 months, 
      pIHPFS = 0.004). The 6- and 12-month OS rates were 91.4% and 68.6% in the 
      combined therapy group and 82.9% and 48.6% in the monotherapy group, 
      respectively. The 6- and 12-month PFS rates were 68.6% and 34.3% in the combined 
      therapy group and 31.4% and 8.6% in the monotherapy group, respectively. 
      Furthermore, a higher ORR was observed in SBRT plus lenvatinib group (54.29% vs. 
      22.86%, p = 0.007). Subgroup analysis of patients with macroscopic vascular 
      invasion (MVI) also had similar results. Moreover, most adverse events (AEs) were 
      mild-to-moderate and manageable in the SBRT plus lenvatinib group. CONCLUSION: 
      SBRT plus lenvatinib is expected to significantly improve OS, PFS, IHPFS, and ORR 
      for patients with advanced HCC when compared to SBRT alone, with manageable 
      adverse effects.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Wang, Quan
AU  - Wang Q
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, No. 100 Xi Si Huan Middle Road, Fengtai 
      District, Beijing, 100039, China.
FAU - Ji, Xiaoquan
AU  - Ji X
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, No. 100 Xi Si Huan Middle Road, Fengtai 
      District, Beijing, 100039, China.
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      China.
FAU - Sun, Jing
AU  - Sun J
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, No. 100 Xi Si Huan Middle Road, Fengtai 
      District, Beijing, 100039, China.
FAU - Li, Wengang
AU  - Li W
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, No. 100 Xi Si Huan Middle Road, Fengtai 
      District, Beijing, 100039, China.
FAU - Duan, Xuezhang
AU  - Duan X
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, No. 100 Xi Si Huan Middle Road, Fengtai 
      District, Beijing, 100039, China. duanxuezhang2006@163.com.
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      China. duanxuezhang2006@163.com.
FAU - Zhang, Aimin
AU  - Zhang A
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, No. 100 Xi Si Huan Middle Road, Fengtai 
      District, Beijing, 100039, China. zhangaimin761213@163.com.
LA  - eng
GR  - 82003211/This research was funded by National Natural Science Foundation of 
      China./
PT  - Journal Article
DEP - 20230323
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - EE083865G2 (lenvatinib)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy/radiotherapy
MH  - *Liver Neoplasms/drug therapy/radiotherapy
MH  - Propensity Score
MH  - *Radiosurgery/adverse effects
MH  - Ubiquitin-Protein Ligases
OTO - NOTNLM
OT  - Advanced hepatocellular carcinoma
OT  - Lenvatinib
OT  - Macrovascular invasion
OT  - Stereotactic body radiotherapy
EDAT- 2023/03/24 06:00
MHDA- 2023/07/31 06:42
CRDT- 2023/03/23 12:14
PHST- 2022/10/30 00:00 [received]
PHST- 2023/02/14 00:00 [accepted]
PHST- 2023/07/31 06:42 [medline]
PHST- 2023/03/24 06:00 [pubmed]
PHST- 2023/03/23 12:14 [entrez]
AID - 10.1007/s00432-023-04652-y [pii]
AID - 10.1007/s00432-023-04652-y [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 Aug;149(10):7441-7452. doi: 
      10.1007/s00432-023-04652-y. Epub 2023 Mar 23.